viral drug resistance

Summary

Summary: The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.

Top Publications

  1. ncbi Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
  2. ncbi Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes
    Birgitte B Simen
    454 Life Sciences, a Roche Company, Branford, Connecticut, USA
    J Infect Dis 199:693-701. 2009
  3. ncbi Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
    Jeffrey A Johnson
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Med 5:e158. 2008
  4. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
  5. ncbi Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
    Diane E Bennett
    World Health Organization, Geneva, Switzerland
    PLoS ONE 4:e4724. 2009
  6. ncbi Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
  7. ncbi Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States
    Nila J Dharan
    Epidemic Intelligence Service, Office of Workforce and Career Development Assigned to Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS A 32, Atlanta, GA 30333, USA
    JAMA 301:1034-41. 2009
  8. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
  9. ncbi Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
    Peter Angus
    Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
    Gastroenterology 125:292-7. 2003
  10. ncbi The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
    Rupert J Russell
    MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    Nature 443:45-9. 2006

Research Grants

Detail Information

Publications196 found, 100 shown here

  1. ncbi Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
  2. ncbi Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes
    Birgitte B Simen
    454 Life Sciences, a Roche Company, Branford, Connecticut, USA
    J Infect Dis 199:693-701. 2009
    ..Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important...
  3. ncbi Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
    Jeffrey A Johnson
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Med 5:e158. 2008
    ..We used sensitive and simple tests to investigate evidence of transmitted drug resistance in antiretroviral drug-naïve persons and assess the clinical implications of minority drug-resistant variants...
  4. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
    ..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
  5. ncbi Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
    Diane E Bennett
    World Health Organization, Geneva, Switzerland
    PLoS ONE 4:e4724. 2009
    ..The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions...
  6. ncbi Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
    ..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
  7. ncbi Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States
    Nila J Dharan
    Epidemic Intelligence Service, Office of Workforce and Career Development Assigned to Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS A 32, Atlanta, GA 30333, USA
    JAMA 301:1034-41. 2009
    ..Early surveillance data suggest that the prevalence of oseltamivir resistance among A(H1N1) viruses will most likely be higher during the 2008-2009 season...
  8. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  9. ncbi Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
    Peter Angus
    Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
    Gastroenterology 125:292-7. 2003
    ..The aim of this study was to characterize adefovir resistance in a patient who developed clinical and virologic evidence of breakthrough during a 96-week course of treatment...
  10. ncbi The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
    Rupert J Russell
    MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    Nature 443:45-9. 2006
    ..Our analysis suggests that it may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs...
  11. ncbi Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults
    Christian Laurent
    Institut de Recherche pour le Développement and Department of International Health, University of Montpellier UMR 145, France
    J Acquir Immune Defic Syndr 38:14-7. 2005
    ....
  12. ncbi Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Infect Dis 48:239-47. 2009
    ..Therefore, we evaluated the possible role of minority quasispecies of drug-resistant human immunodeficiency virus type 1, which are undetectable at baseline by population sequencing, with regard to early virological failure...
  13. ncbi Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients
    Eugene R Schiff
    Center for Liver Diseases, University of Miami, Miami, FL 33136, USA
    Hepatology 38:1419-27. 2003
    ..In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements in virologic, biochemical, and clinical parameters in CHB patients pre- and post-LT with lamivudine-resistant HBV...
  14. ncbi Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
    Anna S Lok
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 46:254-65. 2007
    ..Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy...
  15. ncbi Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
    Patrick J Collins
    MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK
    Nature 453:1258-61. 2008
    ..7) and H1N1 (ref. 8) viruses with neuraminidases carrying these mutations, our results indicate that it would be prudent for pandemic stockpiles of oseltamivir to be augmented by additional antiviral drugs, including zanamivir...
  16. ncbi Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
    Jose R Arribas
    Internal Medicine Service, Hospital de La Paz, Madrid, Spain
    J Acquir Immune Defic Syndr 47:74-8. 2008
    ..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important...
  17. ncbi Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients
    Pietro Lampertico
    A M and A Migliavacca Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Gastroenterology 133:1445-51. 2007
    ..We assessed whether this risk could be overcome by adefovir-lamivudine combination therapy...
  18. ncbi A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus
    Yacine Abed
    Research Center in Infectious Diseases of the CHUQ-CHUL, , Canada
    Antivir Ther 9:577-81. 2004
    ..The replication capacity of both mutants, in particular that of the His274Tyr virus, was impaired when compared with the wild-type virus in vitro...
  19. ncbi Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa
    Vincent C Marconi
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02139, USA
    Clin Infect Dis 46:1589-97. 2008
    ..The prevalence of resistance was assessed among patients from KwaZulu Natal, South Africa, following failure of their first highly active antiretroviral therapy (HAART) regimen...
  20. ncbi Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08
    Siri H Hauge
    Norwegian Institute of Public Health, Oslo, Norway
    Emerg Infect Dis 15:155-62. 2009
    ..The ability of these viruses to sustain their fitness and spread among persons should be considered when shaping future strategies for treating and preventing seasonal and pandemic influenza...
  21. ncbi New antivirals and drug resistance
    Peter M Colman
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia 3050
    Annu Rev Biochem 78:95-118. 2009
    ..However, other factors, such as entropy compensation and solvent anchoring, might also be exploited for improved drug design...
  22. ncbi Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors
    Pavel Pugach
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA
    Virology 377:401-7. 2008
    ..The need to preserve NAb resistance may therefore be a constraint upon how escape from CCR5 inhibitors occurs in vivo...
  23. ncbi Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007
    Masato Tashiro
    WHO Collaborating Center for Reference and Research on Influenza, National Institute of Infectious Diseases, Tokyo, Japan
    Antivir Ther 14:751-61. 2009
    ..High usage of the neuraminidase inhibitor (NAI) oseltamivir in Japan since 2003 led the Neuraminidase Inhibitor Susceptibility Network to assess the susceptibility of community isolates of influenza viruses to oseltamivir and zanamivir...
  24. ncbi Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy
    Olivia Peuchant
    Virology Laboratory, Bordeaux University Hospital, Bordeaux, France
    AIDS 22:1417-23. 2008
    ..We investigated the clinical relevance of the detection of majority and minority-resistant variants in an observational study in antiretroviral therapy naive, recently infected patients...
  25. ncbi Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations
    Yumi Mitsuya
    Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    J Virol 82:10747-55. 2008
    ....
  26. ncbi Genetic analysis of HIV type 1 strains from newly infected untreated patients in cyprus: high genetic diversity and low prevalence of drug resistance
    Ioanna Kousiappa
    Department of Biological Sciences, University of Cyprus, 1678 Nicosia, Cyprus
    AIDS Res Hum Retroviruses 25:23-35. 2009
    ..Taken together, these findings demonstrate that HIV-1 infection in Cyprus is being replenished by a continuous influx of new strains from many countries, establishing an ever-evolving and polyphyletic infection in the island...
  27. ncbi Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)
    Catherine S Adamson
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, Frederick, MD 21702 1201, USA
    J Virol 83:4884-94. 2009
    ..These findings offer insights into the effect of PIR mutations on the evolution of BVM resistance in PI-experienced patients...
  28. ncbi Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 201:1063-71. 2010
    ....
  29. ncbi Influenza virus susceptibility and resistance to oseltamivir
    Fred Y Aoki
    Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Antivir Ther 12:603-16. 2007
    ..However, continued vigilance, especially of emerging avian H5N1 strains, combined with careful, systematic laboratory-based monitoring, is essential...
  30. ncbi Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine
    Denise Lecossier
    INSERM U552, , Paris, France
    J Acquir Immune Defic Syndr 38:37-42. 2005
    ..These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens...
  31. ncbi Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    Mike Westby
    Globel Research and Development, Pfizer Ltd, Sandwich Labs, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
    J Virol 81:2359-71. 2007
    ..This hypothesis was further corroborated by the observation that a high concentration of maraviroc blocks the activity of aplaviroc against maraviroc-resistant virus...
  32. ncbi Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype
    Richard S Kornbluth
    Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0676, USA
    Antimicrob Agents Chemother 50:4038-43. 2006
    ..These findings suggest that drug therapy for poxviruses may be complicated by drug resistance but that treatment of the infection with currently known compounds is possible...
  33. ncbi Structure and mechanism of the M2 proton channel of influenza A virus
    Jason R Schnell
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 451:591-5. 2008
    ..Drug-resistance mutations are predicted to counter the effect of drug binding by either increasing the hydrophilicity of the pore or weakening helix-helix packing, thus facilitating channel opening...
  34. ncbi The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
    Olivier Delelis
    LBPA, CNRS, Ecole Normale Superieure de Cachan, 94235 Cachan, France
    Nucleic Acids Res 37:1193-201. 2009
    ..Altogether, these results account for the predominance of G140S/Q148H mutants in clinical trials using Raltegravir...
  35. ncbi Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, People s Republic of China
    Clin Infect Dis 36:687-96. 2003
    ..Patients with YMDD variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy...
  36. ncbi Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use
    Arnold S Monto
    University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    Antimicrob Agents Chemother 50:2395-402. 2006
    ..The frequency of variants with decreased sensitivity to the NAIs did not increase significantly during this period, but continued surveillance is required, especially in regions with higher NAI use...
  37. ncbi Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi
    Kelita Kamoto
    HIV Unit, Ministry of Health, Lilongwe, Malawi
    Antivir Ther 13:83-7. 2008
    ..Owing to capacity constraints, standard patient care, treatment initiation and follow up are based on World Health Organization (WHO) clinical staging and do not provide laboratory monitoring to assess treatment failure...
  38. ncbi Response to antiretroviral therapy after a single, peripartum dose of nevirapine
    Shahin Lockman
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 356:135-47. 2007
    ..A single dose of nevirapine during labor reduces perinatal transmission of human immunodeficiency virus type 1 (HIV-1) but often leads to viral nevirapine resistance mutations in mothers and infants...
  39. ncbi Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors
    F Damond
    , Paris, France
    J Clin Microbiol 43:484-7. 2005
    ..Substitutions selected under treatment were observed at positions corresponding to HIV-1 resistance mutations as well as at positions of currently unknown impact on HIV-1...
  40. ncbi Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use
    Thuy Le
    Yale University School of Medicine, New Haven, CT, USA
    PLoS ONE 4:e6079. 2009
    ..Further, the clinical implications of low-abundance drug-resistant variants at time of virologic failure are unknown...
  41. ncbi Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response
    Koen Deforche
    Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    Antivir Ther 13:399-407. 2008
    ..A method has been developed to estimate a fitness landscape experienced by HIV-1 under treatment selective pressure as a function of the genotypic sequence thereby also estimating the genetic barrier to resistance...
  42. ncbi Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission
    Jessica D Church
    School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 198:1075-82. 2008
    ..We analyzed NVP resistance in HIV-infected Ugandan infants who received either SD NVP or extended NVP prophylaxis...
  43. ncbi Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus
    Natalia A Ilyushina
    Division of Virology, Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Gen Virol 88:1266-74. 2007
    ..Our finding reveals that sequence analysis of the transmembrane domain of M2 protein may not adequately identify all drug-resistant variants...
  44. ncbi Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients
    Jens Verheyen
    Institute of Virology, University of Cologne, Cologne, Germany
    Antivir Ther 11:879-87. 2006
    ..Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses...
  45. ncbi Resistant influenza A viruses in children treated with oseltamivir: descriptive study
    Maki Kiso
    Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Lancet 364:759-65. 2004
    ..Furthermore, children can be a source of viral transmission, even after 5 days of treatment with oseltamivir...
  46. ncbi Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1
    Megan Wind-Rotolo
    Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Infect Dis 199:1301-9. 2009
    ..Although resistant viruses fade to undetectable levels in plasma, they may persist as stably integrated proviruses within the latent reservoir in resting CD4(+) T cells, potentially complicating future treatment...
  47. ncbi Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus
    Qi Shi Du
    Guangxi Academy of Sciences, Nanning, Guangxi, China
    J Theor Biol 259:159-64. 2009
    ..The findings reported here may stimulate and encourage new strategies for developing effective drugs against influenza A, particularly in dealing with the drug-resistant problems...
  48. ncbi Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections
    Bin Wang
    Retroviral Genetics Laboratory, Center for Virus Research, Westmead Millennium Institute, Westmead, NSW 2145, Australia
    Antiviral Res 87:16-21. 2010
    ..In the light of emerging resistance, close monitoring and understanding of the nature and dynamics of resistance mutations in newly emerging strains should be a priority...
  49. ncbi Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations
    Jerome Deval
    Architecture et Fonction des Macromolecules Biologiques, UMR 6098 CNRS et Université Aix Marseille I et II, ESIL, Campus de Luminy, 13288 Marseille Cedex 09, France
    J Biol Chem 279:509-16. 2004
    ..All together, these results define at the molecular level how nucleoside-resistant viruses can be driven to reduced viral fitness...
  50. ncbi Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing
    Soo-Yon Rhee
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA
    Antimicrob Agents Chemother 48:3122-6. 2004
    ..Characterization of the phenotypic and clinical significance of these common patterns may lead to improved treatment recommendations for a large proportion of patients for whom antiretroviral therapy is failing...
  51. ncbi Algorithms for the interpretation of HIV-1 genotypic drug resistance information
    Jurgen Vercauteren
    Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
    Antiviral Res 71:335-42. 2006
    ..Successful therapy heavily relies on the expertise of the clinician...
  52. ncbi Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort
    Brendan A I Payne
    Department of Infection and Travel Medicine, James Cook University Hospital, Middlesbrough, UK
    J Antimicrob Chemother 62:464-8. 2008
    ..To describe current practice in testing for transmitted antiretroviral drug resistance (TDR) and the prevalence of TDR in a large UK HIV-1 cohort...
  53. ncbi Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread
    Andreas Handel
    Department of Biology, Emory University, Atlanta, Georgia, United States of America
    PLoS Comput Biol 3:e240. 2007
    ..Better knowledge of the quantitative dynamics of the immune response during influenza infections will be crucial to further improve the results...
  54. ncbi Antiviral drug resistance: clinical consequences and molecular aspects
    Angeline Bartholomeusz
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Semin Liver Dis 26:162-70. 2006
    ....
  55. ncbi Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
    Hongmei Mo
    Department R47D, Building AP52N, Abbott Laboratories, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Virol 79:3329-38. 2005
    ....
  56. ncbi Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
    Annemarie M J Wensing
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
    J Infect Dis 192:958-66. 2005
    ..These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated...
  57. ncbi Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004
    Visva Pillay
    National Institute for Communicable Diseases, Johannesburg, South Africa
    Antivir Ther 13:101-7. 2008
    ....
  58. ncbi Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006
    Gugu Maphalala
    Swaziland Ministry of Health and Social Welfare, National Reference Laboratory, Mbabane, Swaziland
    Antivir Ther 13:95-100. 2008
    ..We used the WHO's HIVDR threshold survey method to assess transmitted HIVDR in three antenatal clinic (ANC) sites along the corridor between the two most populous cities in Swaziland, where ART was introduced in 2003...
  59. ncbi What can modeling tell us about the threat of antiviral drug resistance?
    Sally Blower
    AIDS Institute and Department of Biomathematics, David Geffen School of Medicine, University of California at Los Angeles, California 90095 1766, USA
    Curr Opin Infect Dis 15:609-14. 2002
    ..Here, we review how mathematical models have been used to provide insights into the emerging threat of antiviral resistance. We focus mainly on the problem of drug resistance to HIV...
  60. ncbi Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations
    Fernando A Frankel
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 21:665-75. 2007
    ..To determine the underlying biochemical mechanisms responsible for the diminished viral replicative capacity associated with K65R/M184V-containing viruses...
  61. ncbi Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    Gastroenterology 132:1767-77. 2007
    ..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur...
  62. ncbi Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
    Kazuya Shimura
    Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, 53 Kawaramachi, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    J Virol 82:764-74. 2008
    ....
  63. ncbi Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 11:701-5. 2006
    ..This study examined whether, in the context of a first-line abacavir/lamivudine highly active antiretroviral therapy (HAART) regimen, K65R might occur as a minority population where L74V was detected at virological failure...
  64. ncbi Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 11:631-5. 2006
    ..There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r), particularly in antiretroviral (ARV)-naive patients...
  65. ncbi Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy
    Fabiana M Kakehasi
    Maternal and Pediatric AIDS Group, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    AIDS Res Hum Retroviruses 23:1515-20. 2007
    ..Women previously exposed to ART for PMTCT who will start HIV treatment should have genotypic resistance testing performed...
  66. ncbi The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients
    Joe Sasadeusz
    The Alfred Hospital, Melbourne, Victoria, Australia
    AIDS 22:947-55. 2008
    ....
  67. ncbi Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Maria Mercedes Santoro
    Department of Experimental Medicine, Tor Vergata University of Rome, Italy
    New Microbiol 29:89-100. 2006
    ....
  68. ncbi Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:3237-43. 2008
    ....
  69. ncbi Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy
    A Jlizi
    Laboratoire de Microbiologie, Hopital Charles Nicolle, Tunis, Tunisia
    Arch Virol 153:1103-8. 2008
    ..Despite the presence of different mutations, the viral variants were still susceptible to other RTIs and PIs that are currently not available in Tunisia. Thus, alternative therapeutic options exist but are not yet accessible...
  70. ncbi High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients
    Silvina Masciotra
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    AIDS 21:2503-11. 2007
    ..Dried blood spots (DBS) are a convenient alternative to plasma for drug resistance testing in resource-limited settings. We investigated the correlation between resistance genotypes generated from DBS and plasma...
  71. ncbi Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
    Robert S Hogg
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS Med 3:e356. 2006
    ..The objective of this study was to determine the impact of the emergence of drug-resistance mutations on survival among persons initiating HAART...
  72. ncbi Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates
    J García-Guerrero
    Medical Services, Castellón Prison, Crtra de Alcora Km 10, 12071, Castellon, Spain
    Eur J Clin Microbiol Infect Dis 25:695-701. 2006
    ..These findings support the use of resistance testing in HIV-infected inmates who must begin antiretroviral therapy, given the high rate of primary resistance to drugs frequently included in the initial treatment regimens...
  73. ncbi Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)
    Odile Launay
    , , Service de Medecine Interne, Hopital Cochin, AP-HP, Paris, France
    Antivir Ther 11:889-99. 2006
    ..CONCLUSIONS: In patients with advanced resistance, treatment simplification prevented resurgence of wild-type HIV, reduced drug burden, but failed to stabilize progression of the immune deficiency...
  74. ncbi Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients
    Bernard Masquelier
    Departement de Virologie et Immunologie biologique, CHU de Bordeaux, France
    Antivir Ther 11:827-30. 2006
    ..To study the antiviral efficacy and the mutations selected by a triple therapy with zidovudine (AZT), lamivudine (3TC) and tenofovir disoproxil fumarate (TDF)...
  75. ncbi [Evolution of HIV resistance mutations in the Valme referral center]
    M Carmen Nogales
    Enferm Infecc Microbiol Clin 25:159. 2007
  76. ncbi Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA
    M R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby Sygehus, Brendstrupgaardvej 100, 8200 Aarhus N, Denmark
    J Clin Virol 39:215-21. 2007
    ..Viral populations defined by 103K/N and 184M/V as linked or single mutations in the HIV-1 reverse transcriptase gene were investigated in plasma samples and compared with previous findings in the CD45RO(+)T cell compartment...
  77. ncbi Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients
    S Gloria Selabe
    HIV and Hepatitis Research Unit, Department of Virology, University of Limpopo, Medunsa Campus, Pretoria, South Africa
    J Med Virol 79:1650-4. 2007
    ....
  78. ncbi HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    Robert W Shafer
    Division of Infectious Diseases, Stanford University, Stanford, California, USA
    AIDS 21:215-23. 2007
    ..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance...
  79. ncbi A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1
    J Garcia Perez
    AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
    J Med Virol 79:127-37. 2007
    ..In conclusion, the assay permits the quantitation of the level of resistance of clinical HIV-1 isolates to PR and RT inhibitors...
  80. ncbi Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy
    Diana Averbuch
    Hadassah University Medical Center, Jerusalem, Israel
    Pediatr Infect Dis J 25:1049-56. 2006
    ..This strategy may be beneficially applied in the treatment of children in Africa, where thymidine analog + lamivudine-based regimen became available recently but further options are limited...
  81. ncbi Incidence of lamivudine resistance associated mutations in pol-gene of HIV-1 in patients from north India: a preliminary report
    N Sachdeva
    Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh
    Indian J Pathol Microbiol 48:337-40. 2005
    ....
  82. ncbi Drug resistance in patients experiencing early virological failure under a triple combination including indinavir
    O Gallego
    Service of Infectious Diseases, Instituto de Salud Carlos III, Barcelona, Spain
    AIDS 15:1701-6. 2001
    ..Therefore, treatment intensification in those patients without resistance, or a selective substitution of nucleosides in those with resistance limited to these compounds, might be justified...
  83. ncbi Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy
    Elena Chiappini
    Division of Paediatrics and Infectious Diseases, Department of Paediatrics, University of Florence, Florence, Italy
    J Med Virol 70:506-12. 2003
    ..The findings suggest, immunological recovery notwithstanding, virological failure is independent of drug-resistant mutations and consequent possible changes in viral fitness...
  84. ncbi Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 77:7736-45. 2003
    ..Further studies are needed to elucidate the precise regions that are essential for these characteristics...
  85. ncbi Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure
    Daniel Gonzalez de Requena
    Pharmacology Unit, Hospital Carlos III, Instituto de Salud Carlos III, 28035 Madrid, Spain
    AIDS Res Hum Retroviruses 19:457-9. 2003
    ..Thus, drug monitoring may be useful to assess treatment adherence and risk of drug resistance in early virological failures. This information may be crucial for choosing the most appropriate rescue intervention...
  86. ncbi Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors
    Sunee Sirivichayakul
    Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    AIDS 17:1889-96. 2003
    ..Switching from d4T/ddI to ZDV/3TC may be associated with a higher incidence of four or more NAM. Thus, suboptimal and dual NRTI therapy is not recommended for global application...
  87. ncbi Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy
    Maria Pia De Pasquale
    Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2372, USA
    J Acquir Immune Defic Syndr 34:37-44. 2003
    ..To determine whether HIV-1 replicates locally in the female genital tract during therapy, and to study whether endocervix is the dominant source of virus in cervicovaginal lavage fluid...
  88. ncbi Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients
    Caroline A Sabin
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 8:301-8. 2003
    ..New formulations of amprenavir, together with boosted regimens, may enhance the activity in the presence of protease inhibitor-resistant virus...
  89. ncbi Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors
    C Peduzzi
    U. O. Malattie Infettive, Ospedale S.M. Annunziata, Firenze, Italy
    J Clin Virol 25:57-62. 2002
    ..62 vs. 80.32% for VG). Rule-based algorithms can reliably interpret genotypic data obtained from most heavily pretreated patients. However, occasional genotypic patterns may be erroneously interpreted without resistance phenotyping...
  90. ncbi Drug resistance mutations during structured treatment interruptions
    Sabine Yerly
    Laboratory of Virology, Geneva University Hospital, Switzerland
    Antivir Ther 8:411-5. 2003
    ..55-fold higher in patients with the M184V/I mutation than in patients without detectable mutation (P=0.007). CONCLUSIONS: The M184V/I mutation is frequently selected during repeated treatment interruptions...
  91. ncbi Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
    ..To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed...
  92. ncbi Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections
    Stephen Taylor
    HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK
    Antivir Ther 8:479-83. 2003
    ..We conclude that in the presence of suboptimal ART, sexually transmitted infections may enhance the spread of drug-resistant HIV-1...
  93. ncbi Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE
    Irina Maljkovic
    Department of Virology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden
    AIDS Res Hum Retroviruses 19:989-97. 2003
    ..It may be important to routinely test for resistance in newly infected cases to improve the choice of drugs for treatment because the virus may revert and resistant forms can become latent...
  94. ncbi Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  95. ncbi Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 8:121-6. 2003
    ..Further studies should clarify whether this is true for other drugs of the nucleoside analogues class...
  96. ncbi Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 8:51-6. 2003
    ..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment...
  97. ncbi Changes in the rate of genotypic resistance to antiretroviral drugs in Spain
    O Gallego
    Instituto de Salud Carlos III, Madrid, Spain
    AIDS 15:1894-6. 2001
    ..In contrast, resistance among pre-treated patients has increased; resistance to all three drug families having been recognized in nearly a quarter of patients...
  98. ncbi Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries
    Laurence Vergne
    University of Montpellier I, Montpellier, France
    J Acquir Immune Defic Syndr 29:165-8. 2002
    ..A continuous surveillance of the circulation of ARV drug-resistant viruses must be organized to guide ARV treatment strategies and policies...
  99. ncbi Mutations associated with genotypic resistance to antiretroviral therapy in treatment naïve HIV-1 infected patients in Greece
    E Magiorkinis
    Department of Hygiene and Epidemiology, National Retrovirus Reference Center, Athens School of Medicine, University of Athens, Alexanfroupoles 25, GR-115 27, Greece
    Virus Res 85:109-15. 2002
    ..The clinical significance of the polymorphisms associated with reduced susceptibility to NNRTIs remains to be clarified...
  100. ncbi HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options
    Roberto Manfredi
    J Acquir Immune Defic Syndr 30:258-60. 2002
  101. ncbi Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    AIDS 16:1331-40. 2002
    ..CONCLUSIONS: Our data confirm the association among individual pharmacokinetic parameters, genotype pattern and virological response to NFV-containing regimens...

Research Grants84

  1. CMV RETINITIS AND VIRAL DRUG RESISTANCE
    DOUGLAS JABS; Fiscal Year: 1993
    ..The' study will determine: 1) the incidence and prevalence of resistant CMV; 2) risk factors for the development of resistant CMV (e.g. duration of anti-CMV therapy); and 3) the relationship between viral resistance and clinical outcome...
  2. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2007
    ....
  3. INTEGRATE/PHARMACOKINETIC/ANTIRETROVIRUS RESISTANCE TEST
    Edward Acosta; Fiscal Year: 2006
    ..b>Viral drug resistance is a continuum; a certain fold-change in virus susceptibility does not necessitate a drug will be inactive ..
  4. Correlates of Monocyte-Associated Virus in HIV Neurocognitive Impairment
    WALTER contact ROYAL; Fiscal Year: 2010
    ..motifs associated with NCI, and to study the relationship to viral subtype and the relationship of viral drug resistance in different compartments to NCI...
  5. ANTIVIRAL RESISTANCE IN AIDS
    Douglas Richman; Fiscal Year: 2004
    ....
  6. MOLECULAR GENETICS OF HSV DNA POLYMERASE GENE
    Donald Coen; Fiscal Year: 2009
    ..A combination of genetic, virological, biochemical, and crystallographic approaches will be initiated. Efforts to discover new agents that exploit this interaction (and to understand their mechanisms) will also begin. ..
  7. A cell-based assay to measure HCV drug susceptibility
    Neil Parkin; Fiscal Year: 2004
    ....
  8. Drug Resistance and Pathogenesis in Subtype C HIV-1
    David Katzenstein; Fiscal Year: 2007
    ..ARV therapy is expected to dramatically increase in developing countries, and viral drug resistance evolution will inevitably take place...
  9. CFS FLUID AFTER RETROVIRAL TREATMENT FOR HIV
    Richard Price; Fiscal Year: 2000
    ..Antiviral effects will be correlated with the kinetics of drug entry into the CSF. ..
  10. DAART+ AS A STRUCTURAL HIV INTERVENTION IN METHADONE MAINTENANCE
    James Sorensen; Fiscal Year: 2007
    ..Non-adherence results in poor response to therapy, viral drug resistance, cross-resistance and the spread of drug-resistant viral strains...
  11. MOLECULAR GENETICS OF HSV DNA POLYMERASE GENE
    James M Hogle; Fiscal Year: 2010
    ..A combination of genetic, virological, biochemical, and crystallographic approaches will be initiated. Efforts to discover new agents that exploit this interaction (and to understand their mechanisms) will also begin. ..
  12. Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
    Stefan Sarafianos; Fiscal Year: 2009
    ..efficiently, and by doing so, it will help develop anti- HIV therapeutics that are both less susceptible to current clinically significant resistance mutations as well as more refractory to the development of viral drug resistance.
  13. Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
    Stefan Sarafianos; Fiscal Year: 2010
    ..efficiently, and by doing so, it will help develop anti- HIV therapeutics that are both less susceptible to current clinically significant resistance mutations as well as more refractory to the development of viral drug resistance.
  14. Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
    Stefan Sarafianos; Fiscal Year: 2009
    ..efficiently, and by doing so, it will help develop anti- HIV therapeutics that are both less susceptible to current clinically significant resistance mutations as well as more refractory to the development of viral drug resistance.
  15. Combinatorial Chemistry for HIV Entry Inhibitors
    THOMAS NORTH; Fiscal Year: 2007
    ..Future plans are to test the drugs and strategies in our SHIV/rhesus macaque models for mucosal membrane transmission and AIDS. ..
  16. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 1999
    ..W. Lawrence Drew (UCSF) and from Dr. Alejo Erice (University of Minnesota). ..
  17. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2003
    ....
  18. DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORS
    Arun Ghosh; Fiscal Year: 2009
    ..This research integrates organic synthesis, protein-ligand x-ray crystallography, molecular modeling and in-depth virus and cell-biological studies to design the next generation of HIV-1 protease inhibitors. ..
  19. BIOCHEMICAL ASPECTS OF CHEMOTHERAPY
    Yung Chi Cheng; Fiscal Year: 2007
    ....